OLA1 is a potential prognostic molecular biomarker for endometrial cancer and promotes tumor progression

Dong,Yanqi; Yin,Aiqi; Xu,Caiqu; Jiang,Huiping; Wang,Qinghai; Wu,Wenjuan; Guo,Suiqun

doi:10.3892/ol.2021.12837

OLA1 is a potential prognostic molecular biomarker for endometrial cancer and promotes tumor progression

Authors:
- Yanqi Dong
- Aiqi Yin
- Caiqu Xu
- Huiping Jiang
- Qinghai Wang
- Wenjuan Wu
- Suiqun Guo
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong 510630, P.R. China
Published online on: June 2, 2021 https://doi.org/10.3892/ol.2021.12837
Article Number: 576
Copyright: © Dong et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Obg‑like ATPase 1 (OLA1) is upregulated in the tumor tissues in different types of cancer. However, the function of OLA1 and its molecular mechanisms in endometrial cancer (EC) remain unknown. The present study aimed to elucidate OLA1 expression level and its biological function in endometrial cancer. The differential expression of OLA1 between EC tissues and non‑cancerous tissues was analyzed using The Cancer Genome Atlas database and clinical samples. The association between clinicopathological characteristics and OLA1 expression was analyzed using bioinformatics analysis. Cell proliferation, migration and invasion were analyzed by short interfering RNA‑mediated knockdown experiments, Cell Counting Kit‑8, 5‑Ethynyl‑2'‑deoxyuridine incorporation, wound healing, Transwell and Boyden assays. The potential signaling pathways associated with OLA1 in endometrial cancer were evaluated by Gene Set Enrichment Analysis. The expression levels of OLA1 in EC tissues were upregulated compared with that in non‑cancerous tissues (P<0.001). Furthermore, patients with worse survival were found to have higher OLA1 expression, and increased OLA1 expression in endometrial cancer associated with clinical stage (P<0.01), histological type (P<0.01), histological grade (P<0.01), menstrual status (P<0.01), cancer status (P<0.05) and distant metastasis (P<0.05). In RL95‑2 and HEC‑1B cell lines, decreased levels of OLA1 inhibited proliferation, invasion and migration, and the TGF‑β signaling pathway, ubiquitin‑mediated proteolysis and Wnt signaling pathway may be involved in these mechanisms. The present study revealed that OLA1 could be a potential prognostic indicator and therapeutic target in endometrial cancer, and that the TGF‑β signaling, Wnt signaling and ubiquitin‑mediated proteolysis pathways may be regulated by OLA1.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2020. CA Cancer J Clin. 70:7–30. 2020. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD, Fuchs HE and Jemal A: Cancer statistics, 2021. CA Cancer J Clin. 71:7–33. 2021. View Article : Google Scholar : PubMed/NCBI
3	Lortet-Tieulent J, Ferlay J, Bray F and Jemal A: International patterns and trends in endometrial cancer incidence, 1978–2013. J Natl Cancer Inst. 110:354–361. 2018. View Article : Google Scholar : PubMed/NCBI
4	Connor EV and Rose PG: Management strategies for recurrent endometrial cancer. Expert Rev Anticancer Ther. 18:873–885. 2018. View Article : Google Scholar : PubMed/NCBI
5	Hamilton CA, Cheung MK, Osann K, Chen L, Teng NN, Longacre TA, Powell MA, Hendrickson MR, Kapp DS and Chan JK: Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer. 94:642–646. 2006. View Article : Google Scholar : PubMed/NCBI
6	Morice P, Leary A, Creutzberg C, Abu-Rustum N and Darai E: Endometrial cancer. Lancet. 387:1094–1108. 2016. View Article : Google Scholar : PubMed/NCBI
7	Janda M, Gebski V, Brand A, Hogg R, Jobling TW, Land R, Manolitsas T, McCartney A, Nascimento M, Neesham D, et al: Quality of life after total laparoscopic hysterectomy versus total abdominal hysterectomy for stage I endometrial cancer (LACE): A randomised trial. Lancet Oncol. 11:772–780. 2010. View Article : Google Scholar : PubMed/NCBI
8	Neri M, Peiretti M, Melis GB, Piras B, Vallerino V, Paoletti AM, Madeddu C, Scartozzi M and Mais V: Systemic therapy for the treatment of endometrial cancer. Expert Opin Pharmacother. 20:2019–2032. 2019. View Article : Google Scholar : PubMed/NCBI
9	Brooks RA, Fleming GF, Lastra RR, Lee NK, Moroney JW, Son CH, Tatebe K and Veneris JL: Current recommendations and recent progress in endometrial cancer. CA Cancer J Clin. 69:258–279. 2019.PubMed/NCBI
10	Leipe DD, Koonin EV and Aravind L: Evolution and classification of P-loop kinases and related proteins. J Mol Biol. 333:781–815. 2003. View Article : Google Scholar : PubMed/NCBI
11	Ding Z, Liu Y, Rubio V, He J, Minze LJ and Shi ZZ: OLA1, a translational regulator of p21, maintains optimal cell proliferation necessary for developmental progression. Mol Cell Biol. 36:2568–2582. 2016. View Article : Google Scholar : PubMed/NCBI
12	Zhang J, Rubio V, Lieberman MW and Shi ZZ: OLA1, an Obg-like ATPase, suppresses antioxidant response via nontranscriptional mechanisms. Proc Natl Acad Sci USA. 106:15356–15361. 2009. View Article : Google Scholar : PubMed/NCBI
13	Jeyabal PV, Rubio V, Chen H, Zhang J and Shi ZZ: Regulation of cell-matrix adhesion by OLA1, the Obg-like ATPase 1. Biochem Biophys Res Commun. 444:568–574. 2014. View Article : Google Scholar : PubMed/NCBI
14	Mao RF, Rubio V, Chen H, Bai L, Mansour OC and Shi ZZ: OLA1 protects cells in heat shock by stabilizing HSP70. Cell Death Dis. 4:e4912013. View Article : Google Scholar : PubMed/NCBI
15	Rosenzweig R, Nillegoda NB, Mayer MP and Bukau B: The Hsp70 chaperone network. Nat Rev Mol Cell Biol. 20:665–680. 2019. View Article : Google Scholar : PubMed/NCBI
16	Schultz A, Olorundami OA, Teng RJ, Jarzembowski J, Shi ZZ, Kumar SN, Pritchard K Jr, Konduri GG and Afolayan AJ: Decreased OLA1 (Obg-Like ATPase-1) expression drives ubiquitin-proteasome pathways to downregulate mitochondrial SOD2 (superoxide dismutase) in persistent pulmonary hypertension of the newborn. Hypertension. 74:957–966. 2019. View Article : Google Scholar : PubMed/NCBI
17	Bai L, Yu Z, Zhang J, Yuan S, Liao C, Jeyabal PV, Rubio V, Chen H, Li Y and Shi ZZ: OLA1 contributes to epithelial-mesenchymal transition in lung cancer by modulating the GSK3β/snail/E-cadherin signaling. Oncotarget. 7:10402–10413. 2016. View Article : Google Scholar : PubMed/NCBI
18	Zhang JW, Rubio V, Zheng S and Shi ZZ: Knockdown of OLA1, a regulator of oxidative stress response, inhibits motility and invasion of breast cancer cells. J Zhejiang Univ Sci B. 10:796–804. 2009. View Article : Google Scholar : PubMed/NCBI
19	Liu J, Miao X, Xiao B, Huang J, Tao X, Zhang J, Zhao H, Pan Y, Wang H, Gao G and Xiao GG: Obg-like ATPase 1 enhances chemoresistance of breast cancer via activation of TGF-β/Smad axis cascades. Front Pharmacol. 11:6662020. View Article : Google Scholar : PubMed/NCBI
20	Yoshino Y, Qi H, Fujita H, Shirota M, Abe S, Komiyama Y, Shindo K, Nakayama M, Matsuzawa A, Kobayashi A, et al: BRCA1-interacting protein OLA1 requires interaction with BARD1 to regulate centrosome number. Mol Cancer Res. 16:1499–1511. 2018. View Article : Google Scholar : PubMed/NCBI
21	Matsuzawa A, Kanno S, Nakayama M, Mochiduki H, Wei L, Shimaoka T, Furukawa Y, Kato K, Shibata S, Yasui A, et al: The BRCA1/BARD1-interacting protein OLA1 functions in centrosome regulation. Mol Cell. 53:101–114. 2014. View Article : Google Scholar : PubMed/NCBI
22	Takahashi M, Chiba N, Shimodaira H, Yoshino Y, Mori T, Sumii M, Nomizu T and Ishioka C: OLA1 gene sequencing in patients with BRCA1/2 mutation-negative suspected hereditary breast and ovarian cancer. Breast Cancer. 24:336–340. 2017. View Article : Google Scholar : PubMed/NCBI
23	Li Y, Liang L, Dai W, Cai G, Xu Y, Li X, Li Q and Cai S: Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer. Mol Cancer. 15:552016. View Article : Google Scholar : PubMed/NCBI
24	Guo S, Xiao Y, Li D, Jiang Q, Zhu L, Lin D, Jiang H, Chen W, Wang L, Liu C, et al: PGK1 and GRP78 overexpression correlates with clinical significance and poor prognosis in Chinese endometrial cancer patients. Oncotarget. 9:680–690. 2017. View Article : Google Scholar : PubMed/NCBI
25	Zhang YF, Xu QX, Liao LD, Xu XE, Wu JY, Shen J, Wu ZY, Shen JH, Li EM and Xu LY: κ-Opioid receptor in the nucleus is a novel prognostic factor of esophageal squamous cell carcinoma. Hum Pathol. 44:1756–1765. 2013. View Article : Google Scholar : PubMed/NCBI
26	Xiao YY, Lin L, Li YH, Jiang HP, Zhu LT, Deng YR, Lin D, Chen W, Zeng CY, Wang LJ, et al: ZEB1 promotes invasion and metastasis of endometrial cancer by interacting with HDGF and inducing its transcription. Am J Cancer Res. 9:2314–2330. 2019.PubMed/NCBI
27	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
28	R Core Team: R: A language and environment for statistical computing. R Foundation for Statistical Computing; Vienna, Austria: 2012
29	Chigri F, Sippel C, Kolb M and Vothknecht UC: Arabidopsis OBG-like GTPase (AtOBGL) is localized in chloroplasts and has an essential function in embryo development. Mol Plant. 2:1373–1383. 2009. View Article : Google Scholar : PubMed/NCBI
30	Maiti P, Kim HJ, Tu YT and Barrientos A: Human GTPBP10 is required for mitoribosome maturation. Nucleic Acids Res. 46:11423–11437. 2018.PubMed/NCBI
31	Urick ME and Bell DW: Clinical actionability of molecular targets in endometrial cancer. Nat Rev Cancer. 19:510–521. 2019. View Article : Google Scholar : PubMed/NCBI
32	de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, Colombo A, et al: Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): Final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 19:295–309. 2018. View Article : Google Scholar : PubMed/NCBI
33	Flanagan DJ, Vincan E and Phesse TJ: Wnt signaling in cancer: Not a binary ON:OFF switch. Cancer Res. 79:5901–5906. 2019. View Article : Google Scholar : PubMed/NCBI
34	Kaemmerer E, Jeon MK, Berndt A, Liedtke C and Gassler N: Targeting Wnt signaling via notch in intestinal carcinogenesis. Cancers (Basel). 11:5552019. View Article : Google Scholar : PubMed/NCBI
35	Nusse R and Clevers H: Wnt/β-catenin signaling, disease, and emerging therapeutic modalities. Cell. 169:985–999. 2017. View Article : Google Scholar : PubMed/NCBI
36	Wang HX, Sharma C, Knoblich K, Granter SR and Hemler ME: EWI-2 negatively regulates TGF-β signaling leading to altered melanoma growth and metastasis. Cell Res. 25:370–385. 2015. View Article : Google Scholar : PubMed/NCBI
37	Batlle E and Massagué J: Transforming growth factor-β signaling in immunity and cancer. Immunity. 50:924–940. 2019. View Article : Google Scholar : PubMed/NCBI
38	Jung B, Staudacher JJ and Beauchamp D: Transforming growth factor β superfamily signaling in development of colorectal cancer. Gastroenterology. 152:36–52. 2017. View Article : Google Scholar : PubMed/NCBI
39	Hu C, Ni Z, Li BS, Yong X, Yang X, Zhang JW, Zhang D, Qin Y, Jie MM, Dong H, et al: hTERT promotes the invasion of gastric cancer cells by enhancing FOXO3a ubiquitination and subsequent ITGB1 upregulation. Gut. 66:31–42. 2017. View Article : Google Scholar : PubMed/NCBI
40	Mani A and Gelmann EP: The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol. 23:4776–4789. 2005. View Article : Google Scholar : PubMed/NCBI